Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Related RGEN
Repligen (RGEN) Shares March Higher, Can It Continue? - Tale of the Tape
Stocks Hitting 52-Week Highs
Related PFE
Top 4 Mid-Cap Stocks In The Oil & Gas Refining & Marketing Industry With The Highest Dividend Yield
Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
In Pursuit of Shire, AbbVie Eyes Lower Taxes in UK (Fox Business)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Most Popular

Related Articles (RGEN + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free